Bruce Broussard, Former Humana CEO, Joins PGxAI as Advisor for Reimbursement Strategy

PGxAI is honored to welcome Bruce Broussard—Humana’s CEO from 2013 to 2024 and an architect of modern value-based care—as its new Advisor for Reimbursement Strategy. During his tenure, Humana became a benchmark for integrated, analytics-driven payment models that simultaneously improved outcomes and reduced total spend.

Bruce’s guidance will enable PGxAI to translate ultra-precision pharmacogenomics into scalable reimbursement pathways that resonate with payers, providers, and health systems worldwide.

About PGxAI

Founded in 2023 and backed by venture capital firm ATEM Capital, PGxAI is at the forefront of AI-driven precision medicine, combining real-world clinical data with advanced genomics research. The company’s proprietary AI platform personalizes drug selection, dosing, and interaction management based on each patient’s unique genetic makeup. Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, serves as CEO & co-founder, alongside Allan Gobbs, a life sciences investor and executive chairman. PGxAI’s advisory board features experts from Stanford University, Thermo Fisher, and GE Healthcare. By partnering with InterSystems and leveraging cutting-edge cloud and HPC technology from leading providers, PGxAI addresses one of healthcare’s most critical needs: ensuring safe and effective treatments for every individual.